Prevpac

Quick links to important sections

Prevpac

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prevpac

Prevpac: What is This Combination Medicine?

Property Description
Active Ingredients Lansoprazole, Amoxicillin, Clarithromycin
Form Capsules (Delayed-release/Standard) and Film-coated tablet
Pharmacological Class H. pylori Eradication Agent (Triple Therapy)
Common Use Elimination of H. pylori bacterium
Origin Synthetic/Semi-synthetic mixture

Prevpac is a designated prescription-only combination product that serves as a unique triple therapy regimen, fundamentally classified as an H. pylori Eradication Agent. This medication is specifically provided as a convenient, pre-packaged treatment kit to ensure the patient receives the three necessary components simultaneously. It is clinically recognized for its high degree of effectiveness in addressing upper gastrointestinal infections. The general purpose of this targeted therapy is the complete systemic elimination of the Helicobacter pylori bacterium responsible for causing certain duodenal ulcers and, critically, to prevent their subsequent recurrence.

The regimen comprises three separate active ingredients: the Proton Pump Inhibitor (PPI) Lansoprazole, alongside two antibiotics: Amoxicillin, a Penicillin antibiotic, and Clarithromycin, a Macrolide antibiotic. This fixed-composition approach, which combines the different dosage forms of capsules and a film-coated tablet for oral administration, is a distinguishing feature. Combining these agents is a strategy to overcome the challenge of bacterial resistance commonly encountered with single-antibiotic regimens.

By incorporating the synthetic acid reducer, Lansoprazole, with the semi-synthetic antibiotics, the Prevpac approach is rooted in an established medical strategy. The strategic benefit is that the combination addresses both the infection and the conducive acidic environment.

Regulatory References

  1. NIH MedlinePlus: Lansoprazole, Amoxicillin, and Clarithromycin

What side effects are possible with Prevpac?

Possible Side Effects and Safety Information

The official safety profile for the Prevpac regimen (Lansoprazole, Amoxicillin, and Clarithromycin) is structured around categories of adverse reactions documented in regulatory sources such as the FDA and EMA. The profile distinguishes between frequently observed effects and rare, serious systemic risks.

Commonly Documented Adverse Reactions

Adverse reactions classified as Common in regulatory documents often involve the gastrointestinal and nervous systems. These may include diarrhea, abdominal pain, nausea, vomiting, and headache. A frequently listed effect is dysgeusia, or an alteration in taste perception.

System-Organ Classes and Serious Reactions

Adverse reactions are formally grouped into system-organ classes. Effects have been documented across the Gastrointestinal, Nervous System, Hepato-biliary, and Immune System categories. Serious adverse reactions officially noted include severe hypersensitivity reactions like anaphylaxis and Stevens-Johnson Syndrome (SJS), as well as cardiac arrhythmias (such as QT prolongation) and hepatic failure.

Population and Duration-Related Safety Notes

The label specifies safety considerations for certain patient groups. Caution is advised for individuals with renal impairment or hepatic dysfunction. Additionally, the Lansoprazole component carries duration-dependent safety patterns: long-term use (typically one year or longer) is associated with an increased risk of osteoporosis-related fractures and hypomagnesemia.

Safety Restrictions

The regimen is contraindicated in patients with a history of severe penicillin allergy. Furthermore, due to the Clarithromycin component, certain drug combinations are prohibited, notably with specific statins (lovastatin and simvastatin) and medications known to prolong the QT interval, due to the risk of serious adverse cardiac events.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Prevpac's components defines specific manifestations and required emergency actions in the event of overdosage. Due to the presence of multiple active ingredients, treatment focuses on the supportive management of symptoms and prompt elimination of the unabsorbed drug.


Documented Overdose Manifestations

Feature Official Regulatory Statements
Gastrointestinal Symptoms Overdosage of the clarithromycin component may present with abdominal pain, vomiting, nausea, and diarrhea.
Renal Findings Amoxicillin overdosage has been associated with crystalluria (crystals in the urine), which in some cases has been documented to lead to renal failure.
Lansoprazole Acute overdosage cases involving up to 600 mg of lansoprazole have reported no adverse reaction.

When Immediate Medical Help is Required

In the event of overdosage, immediate medical help or contacting a Poison Control Center right away is required. Medical attention is necessary to manage severe outcomes, such as the potential for renal failure or the occurrence of convulsions which may be associated with high drug levels in patients with impaired renal function.

Treatment is defined as symptomatic and supportive. The regulatory information notes that no specific antidote is known for the components, and neither lansoprazole nor clarithromycin are significantly removed by standard hemodialysis or peritoneal dialysis. Patients with amoxicillin crystalluria require maintenance of adequate fluid intake and diuresis to reduce risk.

Therapeutic Uses of Prevpac

What Prevpac treats: main uses and benefits

Prevpac is a combination therapy specifically designed to treat infections caused by the bacterium Helicobacter pylori (H. pylori) and to reduce the risk of duodenal ulcer recurrence. By combining three distinct medications into a single administration format, the treatment addresses both the underlying bacterial infection and the physiological environment of the stomach.

Primary Indications

The primary use of this combination therapy is the eradication of H. pylori in patients with current or historical duodenal ulcer disease. H. pylori is a spiral-shaped bacterium that inhabits the mucous lining of the stomach and is a leading cause of peptic ulcers. Eradicating this pathogen is a critical step in allowing the gastric mucosa to heal and preventing the formation of new ulcers.

Therapeutic Components

The effectiveness of the treatment relies on the synergistic action of its three components:

  • Antibacterial Action: Two different antibiotics work together to inhibit the growth of and eliminate the H. pylori bacteria. Using two antibiotics simultaneously helps to increase the success rate of eradication and reduces the likelihood of the bacteria developing resistance to the treatment.
  • Acid Suppression: The third component is a proton pump inhibitor (PPI). This medication decreases the amount of acid produced in the stomach. Reducing gastric acid serves two purposes: it creates an environment where the antibiotics can work more effectively and provides immediate relief to the stomach lining, facilitating the healing of existing ulcers.

Benefits of Combination Therapy

Providing these three medications together offers several clinical benefits:

  • Pathogen Eradication: The primary benefit is the high rate of success in clearing the H. pylori infection from the digestive tract.
  • Ulcer Prevention: By removing the primary cause of irritation and infection, the therapy significantly lowers the chance that a duodenal ulcer will return after the initial healing process.
  • Symptomatic Relief: The reduction in stomach acid helps to alleviate the discomfort and pain often associated with active ulcers and gastric inflammation.
  • Structured Regimen: The integration of the three drugs into a single treatment pack simplifies the process of taking multiple medications, which supports the completion of the full course of therapy.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Prevpac?

The population eligibility for Prevpac, a combination of lansoprazole, amoxicillin, and clarithromycin, is strictly defined by regulatory documents, establishing absolute exclusions and use restrictions.


Eligibility Status

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to any of the three components or their drug classes (PPIs, penicillins, macrolides).
Contraindicated Individuals with specific pre-existing heart conditions, including QT prolongation or ventricular cardiac arrhythmias.
Contraindicated Patients with a history of clarithromycin-associated cholestatic jaundice or uncorrected hypokalemia/hypomagnesemia.
Not Approved Pediatric population (under 18 years) due to safety and efficacy not being established.
Not Recommended Women who are breastfeeding (all components pass into breast milk) and patients with severe renal impairment (CrCl < 30 mL/min).
Use with Caution Individuals with severe hepatic impairment, Myasthenia Gravis, or Systemic Lupus Erythematosus (SLE).

Prevpac is approved exclusively for use in adults aged 18 years and older. Use during pregnancy is restricted, and the clarithromycin component should be avoided unless no alternative is suitable.

What should I know about interactions with other medicines?

Prevpac Interactions with Other Medicines and Products

The interaction profile of Prevpac is complex due to the presence of Lansoprazole, Amoxicillin, and Clarithromycin. Interactions are documented in official regulatory labeling and include several contraindicated combinations, primarily driven by Clarithromycin's documented effect as a strong CYP3A4 enzyme inhibitor.

Formally Documented Contraindicated Combinations

Co-administration with the following substances is prohibited due to the risk of serious adverse events:

  • Selected Statins: Simvastatin and Lovastatin are contraindicated due to the risk of rhabdomyolysis.
  • Select Cardiac and CNS Drugs: Astemizole, Cisapride, Pimozide, and Terfenadine are prohibited due to the risk of QT prolongation and severe cardiac arrhythmias.
  • Ergot Alkaloids: Ergotamine and Dihydroergotamine are contraindicated due to the potential for acute ergot toxicity.
  • Colchicine: Prohibited in patients with pre-existing renal or hepatic impairment.

Other Clinically Significant Interactions

Official documents note that the Lansoprazole component can affect the absorption of other medicines that require an acidic gastric environment, such as Ketoconazole. This component also requires that Sucralfate be administered at least 30 minutes prior to Prevpac to avoid reducing the Lansoprazole component's bioavailability. Furthermore, the co-administration with Warfarin has been associated with increases in INR and prothrombin time, which requires monitoring. The potential for increased exposure of drugs like Tacrolimus due to Lansoprazole's effect on CYP2C19 is also documented, particularly in certain patient metabolizer groups.

Mechanism of Action

Sustained Inhibition of Gastric Acid Secretion

The mechanism of Prevpac begins with Lansoprazole, a proton pump inhibitor, which is converted into an active metabolite. This metabolite forms a covalent, irreversible bond with the H^+/ K^+- ATPase enzyme on the gastric parietal cells. This action inhibits the final step of acid production, leading to a significant elevation of the intragastric pH. The resulting low-acid environment stabilizes the acid-sensitive antibiotics and biologically shifts the H. pylori into a state with increased vulnerability to the antibiotic mechanisms.

Dual-Action Bacterial Cell Wall and Protein Synthesis Disruption

Amoxicillin and Clarithromycin impose complementary biochemical stresses on the bacterium. Amoxicillin targets Penicillin-Binding Proteins (PBPs) to halt bacterial cell wall synthesis, resulting in cellular lysis. Concurrently, Clarithromycin binds to the 50S ribosomal subunit, arresting the crucial translocation step and thereby inhibiting protein production. This dual-target mechanism provides mechanistic redundancy by targeting two essential bacterial functions.

pH-Dependent Mechanistic Potentiation

This final domain describes the synergy where the Lansoprazole-induced pH rise directly potentiates the other mechanisms. The non-acidic environment increases the chemical stability and concentration of the antibiotics at the site of infection, resulting in a mechanistically enhanced combined effect.

Dosage and Administration Information

How to Use Prevpac: Administration Overview

Prevpac is a triple-therapy combination medicine provided in a standardized blister pack, designed for oral administration only. The following details describe the standard procedural use of the therapy.


Standard Dosing and Frequency

Prevpac is administered twice daily (e.g., morning and evening) for the full prescribed course, which is typically 10 or 14 days. Each single dose consists of four components that must be taken together:

  • One Lansoprazole 30 mg Delayed-Release Capsule
  • One Clarithromycin 500 mg Tablet
  • Two Amoxicillin 500 mg Capsules (1000 mg total Amoxicillin)

Key Administration Conditions

All four components must be taken together at each dosing time. There are two primary constraints for the use of this combination:

  1. Timing with Meals: Doses must be taken before eating (on an empty stomach).
  2. Dosage Form Integrity: The capsules and the tablet must be swallowed whole. They should not be crushed, chewed, or opened.

Special Procedural Notes

  • Missed Dose: If a dose is missed, resume the regular schedule at the next designated time. Do not take two doses at once to make up for a missed dose.
  • Population Restrictions: Safety and effectiveness for this combination product have not been established for use in children (pediatric patients). Use is restricted to adults. Furthermore, use is generally not recommended in patients with severe kidney impairment (creatinine clearance less than 30 mL/min), primarily due to the Clarithromycin component.
  • Protocol Structure: The overall procedure is a fixed-dose, fixed-duration protocol, structured to ensure the simultaneous delivery of all three active ingredients for the entire course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prevpac

Evidence for use in Helicobacter pylori (H. pylori) Infection

This section summarizes the available evidence, primarily from randomized controlled trials (RCTs), that have studied the use of Prevpac's triple therapy components exploring outcomes related to extitH. pylori infection in adults. The research examined the combination in patient groups diagnosed with extitH. pylori and generally involved short study periods. Studies monitored for the presence of the bacteria at a specific time point after the study period.

Data show patterns related to the bacteria being undetectable in a majority of the studied populations at the time of measurement. However, evidence quality varies across studies, and different research reports highlighted varying outcomes across different settings. What remains uncertain is how these findings apply to people whose health history includes prior extitH. pylori related research interventions.

Evidence for use in Duodenal Ulcer Related to H. pylori

The studies that examined the combination in adults with a duodenal ulcer where extitH. pylori infection was present also explored outcomes related to monitoring changes in the duodenal ulcer itself. Research highlights changes measured during the study period, where the combination was observed in studies examining the absence of detectable extitH. pylori. When the extitH. pylori was no longer detected, research describes that changes in the duodenal ulcer status were also commonly observed in the studied populations.

Long-term Studies and Follow-up ⏳

The studies that evaluated this combination typically focused on short-term endpoints, often covering periods up to four to twelve weeks after the study began. Research provides context but not individual predictions about what happens years after receiving the study intervention. Long-term effects are not fully established, and certainty remains low regarding sustained changes.

Evidence in Special Populations ‍‍

The results apply primarily to the adult populations studied. Data for certain groups remain insufficient. Few data are available for older adults, and research exploring the treatment was not typically applied in pediatric patients. Comparative evidence is also lacking for pregnant or breastfeeding populations.

What is Still Uncertain About Prevpac

Overall, the certainty remains low regarding the long-term profile of the combination. Findings were mixed when studies looked at different geographic regions or different patient groups. There is limited information to compare this specific three-drug combination to other research interventions that use different components, which makes definitive comparative subgroup findings uncertain.

Frequently Asked Questions (FAQ)

Common questions about Prevpac (FAQ)

Q: Is it normal to feel tired while taking Prevpac?

A: Unusual tiredness or weakness, which is sometimes described as fatigue or malaise, has been listed among the adverse reactions reported in official clinical trials and post-marketing surveillance for the components of Prevpac. While it is noted in regulatory documents, the exact frequency is not always classified as common.

Q: Is Prevpac associated with any changes in stool color or consistency?

A: Yes, regulatory documents note that changes in the digestive system are common. Diarrhea is one of the most frequently reported adverse reactions, which affects stool consistency. Additionally, dark stools and tongue discoloration have been reported during treatment.

Q: Are there specific foods or drinks to avoid while on Prevpac?

A: Official labeling specifies that all doses must be taken on an empty stomach, generally before a meal. Beyond this timing instruction, official regulatory documents do not list general, specific food or drink restrictions that must be completely avoided, as described in official guidelines.

Q: Does Prevpac affect birth control pills?

A: Regulatory sources generally describe that the Clarithromycin component does not usually affect the action of hormonal contraceptives. However, official warnings state that if the medication causes severe vomiting or severe diarrhea that lasts for more than 24 hours, the effectiveness of oral contraceptive pills may potentially be reduced.

Q: Is Prevpac appropriate for older adults (seniors)?

A: Safety and effectiveness have not been specifically established for older adults in dedicated studies. Official prescribing information advises caution due to the potential for age-related changes in the function of the liver and kidneys.

Q: What kind of monitoring is typically done while taking Prevpac?

A: For patients receiving the drug, official documentation describes specific monitoring needs depending on pre-existing conditions. Monitoring is specifically mentioned in regulatory warnings related to the Lansoprazole component when used for long periods. Follow-up is also a consideration for patients with gastric malignancy.

Q: Can Prevpac affect the results of other medical tests?

A: Yes, regulatory documents indicate that the components of Prevpac can affect the results of some tests. For example, the drug’s components can interfere with blood testing needed to monitor the use of blood thinners like warfarin. It is important that laboratory personnel are aware the medication is being used.

Q: Is it necessary to finish the entire Prevpac course if symptoms improve early?

A: The official guidelines describe the drug as a fixed-duration protocol intended to be taken for the full prescribed course. Regulatory information indicates that stopping the regimen early may lead to the failure of the infection to clear up or increase the risk of bacterial resistance.

Q: Is a metallic taste common when taking Prevpac?

A: Yes, a change in taste perception, formally known as dysgeusia, is listed in official documentation as one of the most common adverse reactions reported in clinical trials. This effect is often described as a metallic taste.

Q: Can a person develop resistance to Prevpac?

A: The three-drug combination is specifically designed to combat the issue of bacterial resistance that is often encountered when using a single antibiotic alone. However, official labeling notes that any unnecessary use of antibiotics, including the components of Prevpac, may lead to a reduction in future treatment effectiveness.

Q: Is it possible to take only one part of the Prevpac pack?

A: No, the official administration guidelines strictly state that the combination is a triple-therapy regimen. All three medications must be taken together at each dosing time to ensure the intended combined effect of the regimen is delivered.

Q: Is it safe to drive or operate machinery while taking Prevpac?

A: Official adverse reaction reports include nervous system side effects such as dizziness and confusion. Patients should be aware of how they react to the Prevpac regimen before performing activities that require full mental alertness, such as driving or operating machinery.

Q: Can Prevpac be safely stopped before the full duration if severe side effects occur?

A: In regulatory safety information, individuals are advised to contact a healthcare professional immediately if they experience severe side effects, such as bloody diarrhea, fast or irregular heartbeats, or signs of liver or kidney problems. The decision to stop treatment must be made by a healthcare professional.

Q: Why is it important to take Prevpac exactly as prescribed?

A: The combination is a fixed, synergistic regimen where all components and the full duration are critical. Official labeling states that the medication must be taken for the full prescribed course, as the administration guidelines specify that it must be taken before a meal to support the intended effect.

Q: Does Prevpac cause dizziness or lightheadedness?

A: Yes, dizziness is listed in the adverse reaction section of regulatory documents. However, this effect is officially reported as infrequent.

Q: Can Prevpac cause yeast infections?

A: Yes, official labeling notes that the antibiotic use in this medication may result in oral thrush (a fungal infection in the mouth) or a new vaginal yeast infection, which is often referred to as vaginal moniliasis.

Q: Is there a generic version of Prevpac available?

A: Yes, while the original brand name Prevpac has been discontinued, the FDA’s records confirm that a generic version of the pre-packed combination kit containing Lansoprazole, Amoxicillin, and Clarithromycin is available.

How should Prevpac be stored and disposed of?

The Prevpac combination kit must be stored and handled strictly according to the official requirements detailed on the product labeling.

Storage Requirements

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C. It is a requirement that the product be kept from freezing and protected from excess heat, moisture, and light.

Packaging and Safety

The kit must remain in the original daily packets and storage box with the container kept tightly closed. The medication must be stored in a secure location, out of the sight and reach of children.

Disposal

Users are instructed to consult a healthcare professional for guidance on the proper disposal of any unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prevpac found in:

A-Z Index: